Fig 2: Distribution of tumors overall SSTR5 expression (0 = negative, 1 = weak expression, 2 = moderate expression, 3 = strong expression) according to grade (1–3) of the tumor.

Fig 3: Von Hippel Lindau Disease related hemangioblastomas express somatostatin receptors.Patients with von Hippel Lindau disease (VHL) undergoing surgical resection of posterior fossa hemangioblastoma provide confirmation of DOTATATE avidity of these lesions. The post-operative T1 weighted MRI image (A) and DOTATATE PET image (B) confirm complete resection of a DOTATATE avid posterior fossa hemangioblastoma (C,D). Representative images (E) of anti-SSTR IHC staining classified as negative (i), positive/negative (ii), positive (iii), double positive (iv) or triple positive (v). Scale bar = 50 μm. Average staining intensity for each SSTR subtype is shown in panel F. Number of tumors with SSTR expression are categorized by receptor subtype (G). Positive staining patterns were found in 8/9 tumors against SSTR1, in 8/9 tumors against SSTR2a, in 2/9 tumors against SSTR3, in 9/9 tumors against SSTR4, and in 8/9 tumors in SSTR5.

Fig 4: WB and WLB analysis.A Western blot analysis of the somatostatin receptor using anti-sstr2 (lane sstr2) and anti-sstr5 (lane sstr5) antibodies and a Western ligand blot analysis with FITC-octreotate (lane WLB) of a small-cell lung cancer cell (H69) lysate. All experiments were performed under the same conditions. The locations of the bands in the western blot analysis (the solid arrows of lane sstr2 and the dashed arrow of lane sstr5) correspond approximately to those in the western ligand blot analysis (the solid arrows and dashed arrow of lane WLB). The bands in the western ligand blot analysis (the solid arrows and dashed arrow of lane WLB) were completely blocked by the addition of a large amount of octreotide (X10000) (lane Blocking).

Fig 5: Frequency of SSTR1 and SSTR5 (%) positivity (overall score 2–4) among indolent (n = 19) and malignant (n = 16) tumors.